JP2023502108A5 - - Google Patents
Info
- Publication number
- JP2023502108A5 JP2023502108A5 JP2022528625A JP2022528625A JP2023502108A5 JP 2023502108 A5 JP2023502108 A5 JP 2023502108A5 JP 2022528625 A JP2022528625 A JP 2022528625A JP 2022528625 A JP2022528625 A JP 2022528625A JP 2023502108 A5 JP2023502108 A5 JP 2023502108A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cdr
- cancer
- ror2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936900P | 2019-11-18 | 2019-11-18 | |
| US62/936,900 | 2019-11-18 | ||
| PCT/US2020/061130 WO2021102055A1 (en) | 2019-11-18 | 2020-11-18 | Anti-ror-2 antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023502108A JP2023502108A (ja) | 2023-01-20 |
| JP2023502108A5 true JP2023502108A5 (https=) | 2023-11-21 |
| JP7734661B2 JP7734661B2 (ja) | 2025-09-05 |
Family
ID=75981012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528625A Active JP7734661B2 (ja) | 2019-11-18 | 2020-11-18 | 抗ｒｏｒ－２抗体および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230192846A1 (https=) |
| EP (1) | EP4061848A4 (https=) |
| JP (1) | JP7734661B2 (https=) |
| KR (1) | KR20220113951A (https=) |
| CN (1) | CN116018353A (https=) |
| AU (1) | AU2020388577A1 (https=) |
| BR (1) | BR112022009611A2 (https=) |
| CA (1) | CA3161617A1 (https=) |
| IL (1) | IL293026A (https=) |
| MX (1) | MX2022005949A (https=) |
| WO (1) | WO2021102055A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020248448B2 (en) * | 2019-03-26 | 2026-01-29 | The Regents Of The University Of California | Chimeric antigen receptor modified T-cells (CAR-T) for the treatment of hematological and solid tumor cancers |
| AU2023226070A1 (en) * | 2022-02-25 | 2024-09-05 | Bioatla, Inc. | Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugate |
| EP4642808A2 (en) * | 2022-12-30 | 2025-11-05 | The Regents of the University of California | Anti-ror-2 antibodies and methods of use |
| CN121793989A (zh) | 2023-07-07 | 2026-04-03 | 索尔夫治疗公司 | 药物单元和靶向单元的缀合物及其前体化合物 |
| CN121181696A (zh) * | 2024-06-21 | 2025-12-23 | 深圳大学 | 一种治疗肿瘤的抗体及其应用 |
| WO2026011121A1 (en) | 2024-07-03 | 2026-01-08 | Solve Therapeutics, Inc. | Anti-ror2 antibody-drug conjugates |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007292242A1 (en) * | 2006-09-08 | 2008-03-13 | Genentech, Inc. | Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders |
| GB201506407D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| SG11201806121PA (en) * | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror2 antibody compositions and related methods |
| PL3455261T3 (pl) * | 2016-05-13 | 2022-12-12 | Bioatla, Inc. | Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania |
| JP7010854B2 (ja) * | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| JP7280827B2 (ja) * | 2017-01-18 | 2023-05-24 | エクスマ バイオテック コーポレイション | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
| US11447546B2 (en) | 2017-07-20 | 2022-09-20 | Nbe-Therapeutics Ag | Human antibodies binding to ROR2 |
-
2020
- 2020-11-18 WO PCT/US2020/061130 patent/WO2021102055A1/en not_active Ceased
- 2020-11-18 EP EP20889747.0A patent/EP4061848A4/en active Pending
- 2020-11-18 KR KR1020227019898A patent/KR20220113951A/ko active Pending
- 2020-11-18 JP JP2022528625A patent/JP7734661B2/ja active Active
- 2020-11-18 CN CN202080093841.5A patent/CN116018353A/zh active Pending
- 2020-11-18 AU AU2020388577A patent/AU2020388577A1/en active Pending
- 2020-11-18 MX MX2022005949A patent/MX2022005949A/es unknown
- 2020-11-18 US US17/777,591 patent/US20230192846A1/en active Pending
- 2020-11-18 CA CA3161617A patent/CA3161617A1/en active Pending
- 2020-11-18 BR BR112022009611A patent/BR112022009611A2/pt unknown
- 2020-11-18 IL IL293026A patent/IL293026A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023502108A5 (https=) | ||
| JP2022518925A5 (https=) | ||
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2024023228A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2021512614A5 (https=) | ||
| JP2021519072A5 (https=) | ||
| JP2019509023A (ja) | Ｒｏｒ２抗体組成物及び関連する方法 | |
| JP2022507679A (ja) | Ｈｅｒ２／ｐｄ１二重特異性抗体 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN103998468A (zh) | 抗原结合蛋白及其用作治疗癌症的定位产品的用途 | |
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| CN117603355A (zh) | 结合pd-1的抗体 | |
| JP2021520201A5 (https=) | ||
| JP2024508808A5 (https=) | ||
| JP2021512604A5 (https=) | ||
| US20250018040A1 (en) | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors | |
| CN105452297B (zh) | mAb 2抗-Met抗体 | |
| CA3229160A1 (en) | Bispecific tetravalent antibody targeting egfr and her3 | |
| TWI867218B (zh) | 靶向her2的抗原結合建構體及用途 | |
| AU2021446021A1 (en) | Anti-bcam antibody or antigen-binding fragment thereof | |
| JP2023103439A (ja) | 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤 | |
| CN114539420B (zh) | 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用 | |
| JP2024517760A (ja) | 抗５ｔ４抗体及びその使用 |